Ram Mukunda | Source | CEO at IGC Pharma
Ram Mukunda
Ram is currently serving as Executive Chairman and CEO of IGC, where their mission is to treat pain, Alzheimer's, Parkinson's, PTSD, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions with phytocannabinoid-based treatments. He has extensive experience leading public companies in technology, medical cannabis, vertical and indoor farming, and telecommunications. He is an expert in business modeling, valuation, business strategy, IPOs, secondary financing, PIPES, reverse mergers, SEC and NYSE compliance, SOX requirements among others.
-
IGC Pharma
CEO
-
IGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer’s Association International Conference
IGC 's 6 Posters on Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms of Dementia at 2023 Alzheimer’s Association International Conference.
Article
-
We are honored to have six posters accepted for presentation at AAIC 2023, a prestigious meeting of leading Alzheimer’s disease experts and pharmaceutical innovators. The data being presented at AAIC from our Phase 1 clinical trial of IGC-AD1 demonstrates the positive impact of our patented cannabinoid formulation on neuropsychiatric symptoms such as agitation, apathy, and the associated caregiver distress, without causing suicidal ideation or increasing blood pressure variability. Additionally, we are pleased to announce the presentation of our genotyping study analyzing the pharmacokinetics of THC metabolization in diverse patient groups. IGC is committed to increasing diversity in clinical trials and subsequently developing effective treatments for all who are impacted by Alzheimer’s disease. We are encouraged by the results of IGC-AD1 so far and we continue to drive progress in our Phase 2 trial.
